TICKERNERD
Menu
ARCTARCTHealthcare · Biotechnology

ARCT Stock Forecast: Arcturus Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$15
+3.80% on the day

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. hold a median 12-month price target of $21 — +37.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$418.7M
Ticker Nerd rank
66 / 100
Median analyst target
$21
Analysts covering
13
Revenue$880K−96.4% y/y
Operating income−$25.5M
Net income−$23.8M
Free cash flow−$19.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
+85.8%
YTD
+149.4%
1Y
−11.7%
From 52W high
−34.0%
From 52W low
+176.5%
$6
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcturus Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
79
Accruals
75
Issuance
70
Value
69
Quality
63
Size
56
Momentum
36
Volatility
26
Growth
20

Revisions (79): Analysts have, on balance, been raising their forecasts.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ARCTHigh $41Median $21Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $8Median $21High $41

The green dot is the last close — the median target sits +37.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 July 2026Freedom BrokerInitiatesBuy$27
18 Mar 2026B. Riley SecuritiesInitiatesBuy—
5 Mar 2026CitigroupMaintainsBuy—
4 Mar 2026CitigroupMaintainsNeutral—
4 Mar 2026Piper SandlerMaintainsOverweight—
6 Jan 2026CitigroupMaintainsNeutral—
13 Nov 2025CitigroupMaintainsNeutral—
11 Nov 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2025Piper SandlerMaintainsOverweight—
24 Oct 2025HC Wainwright & Co.DowngradeNeutral—
23 Oct 2025CitigroupDowngradeNeutral—
23 Oct 2025GuggenheimDowngradeNeutral—
23 Oct 2025Wells FargoMaintainsOverweight—
22 Oct 2025BTIGMaintainsBuy—
22 Oct 2025GuggenheimDowngradeNeutral—
4 Sept 2025HC Wainwright & Co.AssumesBuy$60
22 Aug 2025Leerink PartnersMaintainsOutperform—
12 Aug 2025CitigroupMaintainsBuy—
12 Aug 2025Wells FargoMaintainsOverweight—
2 July 2025ScotiabankMaintainsSector Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Arcturus Therapeutics Holdings, Inc. returned −11.7% against +17.0% for the S&P 500, dividends included.

ARCT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26ARCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
1
Fundamentals

Arcturus Therapeutics Holdings, Inc. (ARCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.1×

Cheaper than 58% of US stocks

Price / sales
14.3×

Cheaper than 11% of US stocks

Price / book
2.4×

Cheaper than 39% of US stocks

EV / EBITDA
−2.5×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−89.5%

Higher than 2% of US stocks

Earnings growth (YoY)
−96.4%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−863.3%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.3%

Higher than 22% of US stocks

Return on assets
−24.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arcturus Therapeutics Holdings, Inc. (ARCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arcturus Therapeutics Holdings, Inc. has a market value of $418.7M and an enterprise value of $250.1M.

  • Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter shrank 89.5% year on year.

  • Net income over the same four quarters: −$93.3M, a −498.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.31.

  • Free cash flow in the twelve months to 30 June 2026: −$72.8M.

  • Shares outstanding: 28.4M.

  • Trailing P/E: 10.1×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arcturus Therapeutics Holdings, Inc. employs 106 people — $177K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

ARCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARCTArcturus Therapeutics Holdings, Inc.$418.7M
66
EDITEditas Medicine, Inc.$414.3M
78
LRMRLarimar Therapeutics, Inc.$413.9M
30
AVIRAtea Pharmaceuticals, Inc.$425.9M
67
BNTCBenitec Biopharma, Inc.$410.3M
42
CCCCC4 Therapeutics, Inc.$431.8M
69
RZLTRezolute, Inc.$403.8M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arcturus Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARCT news & analysis

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Arcturus Therapeutics Holdings Inc. presented at Citigroup's Biopharma Back to School Summit 2026, as reflected in a transcript published by Seeking Alpha. The item reports on the company's participation in the conference presentation.

Why it matters — An Arcturus watcher would care because the presentation offers visibility into the company's positioning and updates shared at a major biopharma industry conference.

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Business Wire · 31 Aug 2026neutral

Arcturus Therapeutics announced it will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026, featuring a fireside chat, and Citi's 2026 Biopharma Back to School Conference in New York on September 9. The company, a messenger RNA medicines company focused on liver and respiratory rare disease therapeutics, made the announcement via Business Wire.

Why it matters — ARCT watchers may be interested because investor conference appearances give management opportunities to present the company's mRNA pipeline and rare disease programs to the investment community.

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research · 27 Aug 2026positive

Arcturus Therapeutics (ARCT) experienced a "golden cross" technical signal, with its 50-day simple moving average breaking above its 200-day simple moving average after reaching an important support level. Zacks Investment Research highlighted this development as a potentially favourable technical indicator.

Why it matters — A golden cross is a technical pattern that some ARCT watchers may consider a bullish signal for the stock's price trend.

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

MarketBeat · 12 Aug 2026neutral

Arcturus Therapeutics CEO Joseph Payne discussed the company's mRNA platform, which is centered on two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, during a Canaccord discussion. The vaccine business is intended to support the funding of therapeutic development.

Why it matters — An ARCT watcher would care because the CEO laid out the company's strategic direction, highlighting its rare-disease pipeline and how its vaccine revenue is meant to finance therapeutic programs.

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Arcturus Therapeutics Holdings Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the proceedings. The transcript covers management's discussion of the company's quarterly results and outlook.

Why it matters — A shareholder monitoring ARCT would want to read the transcript for detail on the company's most recent financial performance and strategic commentary.

FAQ

Frequently asked questions about ARCT stock

What is the ARCT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. have a median 12-month price target of $21, with estimates ranging from $8 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARCT stock a buy right now?

Of the 13 analysts covering Arcturus Therapeutics Holdings, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcturus Therapeutics Holdings, Inc. 66 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARCT?

As at 12 Sept 2026, Arcturus Therapeutics Holdings, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).

Will ARCT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +37.3% from the last close, and Ticker Nerd's factor model ranks Arcturus Therapeutics Holdings, Inc. 66 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARCT stock forecast for 2030?

No analyst covering Arcturus Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $41 over the next 12 months.

How has ARCT stock performed over the past year?

Arcturus Therapeutics Holdings, Inc. returned -11.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcturus Therapeutics Holdings, Inc. do?

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders.

What is the latest news on ARCT?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Arcturus Therapeutics Holdings Inc. presented at Citigroup's Biopharma Back to School Summit 2026, as reflected in a transcript published by Seeking Alpha. The item reports on the company's participation in the conference presentation.

Company

About Arcturus Therapeutics Holdings, Inc.

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders. The company’s core platforms include STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system designed to help deliver RNA medicines into the body. Its current work centers on liver and respiratory rare diseases, with programs aimed at conditions such as cystic fibrosis and ornithine transcarbamylase deficiency, alongside vaccine candidates for seasonal and pandemic influenza and COVID-19. Arcturus Therapeutics also supports drug substance and drug product manufacturing capabilities as part of its RNA medicine development and commercialization activities. Headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a specialized role in the biotechnology market by advancing RNA-based approaches for both therapeutic and preventive applications.

CEO Mr. Joseph E. Payne M.Sc. · 106 employees · United States · https://arcturusrx.com